Current and future trends in the oral pharmacotherapy of male erectile dysfunction

Expert Opinion on Investigational Drugs

Volumn 12, Issue 9, 2003, Pages 1521-1533

  Ückert, Stefan ^a,b   Stief, Christian G ^a   Jonas, Udo ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b IPF PHARMACEUTICALS GMBH   (Germany)

Author keywords

Antiserotonergics; Apomorphine; Erectile dysfunction; Growth hormone; Melanocortin; PDE inhibitors; Pharmacotherapy; Phentolamine; sGC activators

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; APOMORPHINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOMIPRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; GLYCERYL TRINITRATE; HORMONE DERIVATIVE; KETANSERIN; MIANSERIN; NITRATE; NITRIC OXIDE SYNTHASE INHIBITOR; PAROXETINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE I; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PLACEBO; SEROTONIN; SERTRALINE; SILDENAFIL; TADALAFIL; TRAZODONE; UNINDEXED DRUG; VARDENAFIL;

BRAIN FUNCTION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORPUS CAVERNOSUM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RELEASE; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DYSPEPSIA; ERECTILE DYSFUNCTION; FATIGUE; FLUSHING; HEADACHE; HUMAN; MALE; MALE GENITAL SYSTEM FUNCTION; MEDICAL RESEARCH; NONHUMAN; NOSE CONGESTION; PENIS ERECTION; REVIEW; SEDATION; SIGNAL TRANSDUCTION; SPINAL CORD FUNCTION; SWEATING; VERTIGO; VISUAL DISORDER;

EID: 0141517121     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.9.1521     Document Type: Review

References (115)

1. KANDEEL FR, KOUSSA VKT, SWERDLOFF RS: Male sexual function and its disorders: physiology, pathophysiology, clinical investigation, and treatment. Endocrine Rev. (2001) 22:342-388.
2. AYTA IA, MCKINLAY JB, KRANE RJ: The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. Br. J. Urol. (1999) 84:50-56.
3. G-nitro-L-arginine on the erectile response to cavernous nerve stimulation in the rabbit. Acta Physiol. Scand. (1991) 143:299-304.
4. G-Nitro-L-arginine inhibits non-adrenergic, non-cholinergic relaxation of human isolated corpus cavernosum. Acta Physiol. Scand. (1991) 141:441-442.
5. IGNARRO LJ, BUSH PA, BUGA GM, WOODS KS, FUKUTO JM, RAJFER J: Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem. Biophys. Res. Comm. (1990) 170:843-850.
6. ANDERSSON K-E, WAGNER G: Physiology of penile erection. Pharmacol. Rev. (1995) 75:191-236.
7. ANDERSSON K-E, HOLMQUIST F: Regulation of tone in penile cavernous smooth muscle. Established concepts and new findings. World J. Urol. (1994) 12:249-261.
8. LINCOLN TM, CORNWELL TL: Intracellular cyclic GMP receptor proteins. FASEB J. (1993) 7:328-338.
9. POZZAN T, RIZUTTO R, VOLPE P, MELDOLESI J: Molecular and cellular physiology of intracellular calcium stores. Physiol. Rev. (1994) 74:595-636.
10. TRUSS MC, BECKER AJ, DJAMILLIAN MH, STIEF CG, JONAS U: Role of the nitric oxide donor linsidomine chlorhydrate (SIN-1) in the diagnosis and treatment of erectile dysfunction. Urology (1994) 44:553-556.
11. HEATON JP, MORALES A, OWEN J: Topical glyceryltrinitrate causes measurable penile arterial dilatation in impotent men. J. Urol. (1990) 143:729-731.
12. ÜDCKERT S, KÜTHE A, STIEF CG, JONAS U: Phosphodiestarase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction. World J. Urol. (2001) 19:14-22 (2001).
13. 1 in erectile failure: a survey of worldwide experience. J. Urol. (1996) 155:802-815.
14. OTTENSEN B, WAGNER G, VIRAG R, FAHRENKRUG J: Penile erection: possible role for vasoactive intestinal polypeptide as a neurotransmitter. Br. J. Med. (1984) 288:9-11.
15. CAHN D, MELMAN A, VALCIC M, CHRIST GJ: Forskolin: a promising new adjunct to intracavernous pharmacotherapy. J. Urol. (1997) 155:1789-1794.
16. HALL IP: Isoenzyme selective phosphodiesterase inhibitors: potential clinical uses. Br. J. Clin. Pharmacol. (1993) 35:1-7.
17. ROTELLA P: Phosphodiesterase 5 inhibitors: current status and potential applications. Nat. Rev. Drug Discov. (2002) 1:674-682.
18. CONTI M, JIN SL: The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol. (1999) 63:1-38.
19. SODERLING SH, BEAVO JA: Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr. Opin. Cell Biol. (2000) 12:174-179.
20. TAHER A, STIEF CG, RAIDA M, JONAS U, FORSSMANN WG: Cyclic nucleotide phosphodiesterase activity in human cavernous smooth muscle and the effect of various selective inhibitors. Int. J. Impot. Res. (1992) 4(Suppl. 2):11.
21. BOOLELL M, ALLEN MJ, BALLARD S et al.: Sildenafil: an orally active Type 5 cGMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int. J. Impot. Res. (1996) 8:47-52.
22. KÜTHE A, WIEDENROTH A, MÄGERT HJ et al.: Expression of different phosphodiesterase genes in human cavernous smooth muscle. J. Urol. (2001) 165:280-283.
23. BALLARD SA, GINGELL CJ, TANG K, TURNER LA, PRICE ME, NAYLOR AM: Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J. Urol. (1998) 159:2164-2171.
24. GOLDSTEIN I, LUE TF, PADMA-NATHAN H, ROSEN RC, STEERS WD, WICKER PA. Oral sildenafil in the treatment of erectile dysfunction. N. Engl. J. Med. (1998) 338:1397-1404.
25. BROCK G: Sildenafil citrate. Drugs Today (2000) 36:125-134.
26. MITKA M: Some men who take VIAGRA die - why? JAMA (2002) 283:590-591.
27. NELSON RP, BARADA JH, COSTABILE, RA et al.: Does renewed sexual activity increase cardiac morbidity? Meta-analysis of the experience with MUSE™. J. Urol. (1999) 161(4, Suppl.):215.
28. COHEN JS: Comparison of FDA reports of patient death associated with sildenafil and with injectable alprostadil. Ann. Pharmacother. (2001) 35:285-298.
29. GEELEN P, DROLET B, RAIL J et al.: Sildenafil (VIAGRA) prolongs cardiac repolarization by blocking rapid component of the delayed rectifier potassium current. Circulation (2000) 102:275-277.
30. ISHIKURA F, BEPPU S, HAMADA T, KHANDHERIA BY, SEWARD JH: Effects of sildenafil citrate (VIAGRA) combined with nitrate on heart. Circulation (2000) 102:2516-2521.
31. STIEF CG, ÜCKERT S, BECKER AJ et al.: Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue. Urology (2000) 55:146-150.
32. CONTI CR, PEPINE CJ, SWEENEY M: Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. Am. J. Cardiol. (1999) 83:29C-34C.
33. ZUSMAN RM, MORALES A, GLASER DB, OSTERLOH IA: Overall cardiovascular profile of sildenafil citrate. Am. J. Cardiol. (1999) 83:35C-44C.
34. SAENZ DE TEJADA I, ANGULO J, CUEVAS P et al.: The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int. J. Impot. Res. (2001) 13:282-290.
35. BISCHOFF E, MONDRITZKI T, NIEWOEHNER U, HANING A, ZIMMER D: Vardenafil improved erections in rabbits longer than expected from plasma half-life. Int. J. Impot. Res. (2002) 14(Suppl. 4):S42.
36. YOUNG J, AUERBACH S, PORST H: Vardenafil, a new selective PDE5 inhibitor, significantly improved all IIEF domains and showed favourable safety profile in patients with erectile dysfunction over 12 weeks. J. Urol. (2001) 165(5, Suppl.):224.
37. GOLDSTEIN I, YOUNG J, FISCHER J: Vardenafil: a new, highly selective PDE5 inhibitor, improves erectile function in patients with diabetes mellitus. Diabetes (2001) 50(Suppl. 2):A114.
38. BROCK G, PADMA-NATHAN H, SEGER M: Efficacy and tolerability of vardenafil in men with erectile dysfunction following radical prostatectomy. Eur. Urol. (2002) 1(Suppl. 1):152.
39. MAZZU A, NICHOLLS A, ZINNY M: Vardenafil: a new highly selective PDE5 inhibitor, interacts minimally with nitroglycerin in healthy middle-aged subjects. Int. J. Impot. Res. (2001) 13(Suppl. 5):S64.
40. THADANI U, MAZZU A: Exercise-induced ischemia was not adversely affected by vardenafil during exercise stress test in men with coronary artery disease. Eur. Urol. (2002) 1(Suppl. 1):151.
41. EARDLY I, CARTLEDGE J: Tadalafil (CIALIS) for men with erectile dysfunction. Int. J. Clin. Pract. (2002) 56:300-304.
42. YUASA K, KOTERA J, FUJISHIGE K, MICHIRATA H, SASAKI T, OMORI K: Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expression. J. Biol. Chem. (2000) 275:31469-31479.
43. BROCK GB, MCMAHON CG, CHEN KK et al.: Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J. Urol. (2002) 168:1332-1336.
44. GUILIANO F, VARANESE L: Tadalafil: a novel treatment for erectile dysfuncion. Eur. Heart J. (2002) 4(Suppl. H):H24-H31.
45. GEBEKOR E, BETHELL S, FAWCETT L: Selectivity of sildenafil and other phosphodiesterase Type 5 inhibitors against all human phosphodiesterase families. Eur. Urol. (2001) 1(Suppl. 1):63.
46. EMMICK JT, STUEWE SR, MITCHELL M: Overview of the cardiovascular effects of tadalafil. Eur. Heart J. (2002) 4(Suppl. H):H32-H47.
47. ANDERSSON K-E, STIEF CG: Penile erection and cardiac risk: pathophysiologic and pharmacologic mechanisms. Am. J. Cardiol. (2000) 86(Suppl.):23F-26F.
48. COTZIAS GC, VAN WOERT MH, SCHIFFER LM: Aromatic amino acids and modification of parkinsonism. N. Engl. J. Med. (1967) 276:374-379.
49. LAL S: Apomorphine in the evaluation of dopaminergic function in man. Prog. Neuropsychopharmacol. Biol. Psychiatry (1988) 12:117-164.
50. RAMPIN O: Mode of action of a new oral treatment for erectile dysfunction: apomoprhine SL. BJU Int. (2001) 88(Suppl. 3):22-24.
51. ÜCKERT S, BECKER AJ, NESS BO et al.: Oxytocin plasma levels in the systemic and cavernous blood of healthy males during different penile conditions. World J. Urol. (2003) 20:323-326.
52. BUJIS RM: Intra- and extrahypothalamic vasopressin and oxytocin pathways in the rat. Cell Tissue Res. (1978) 192:423-435.
53. MELIS MR, ARGIOLAS A: Nitric oxide synthase inhibitors prevent apomorphine-and oxytocin-induced penile erection and yawning in male rats. Brain Res. Bull. (1993) 32:71-74.
54. STIEF CG, PADLEY RJ, PERDOK RJ, SLEEP DJ: Cross-study review of the clinical efficacy of Apomorphine SL 2 and 3 mg: pooled data from the three placebo-controlled, fixed-dose crossover studies. Eur. Urol. (2002) 1(3, Suppl.):12-20.
55. BUVAT J, MONTORSI F: Safety and tolerability of Apomorphine SL in patients with erectile dysfunction. BJU Int. (2001) 88(Suppl. 3):30-35.
56. 1a receptor. Brain Res. (1999) 821:414-425.
57. TANG Y, RAMPIN O, CALAS A, FACCHINETTI P, GUILIANO F: Oxytocinergic and serotonergic innervation of identified lumbosacral nuclei controlling penile erection in the male rat. Neuroscience (1998) 82:241-254.
58. WITT MA, GRANTMYRE JE: Ejaculatory failure. World J. Urol. (1993) 11:89-95.
59. SVENSSON L, HANSEN S: Spinal monoaminergic modulation of masculine copulatory behaviour in the rat. Brain Res. (1984) 302:315-321.
60. GORZALKA BB, MENDELSON SD, WATSON NV: Serotonin receptor subtypes and sexual behaviour. Ann. NY Acad. Sci. (1990) 600:445-446.
61. 2 antagonist, in the treatment of sexual dysfunction induced by serotonin reuptake inhibitors. Clin. Neuropharmacol. (1997) 20:210-214.
62. ÜCKERT S, FUHLENRIEDE MH, BECKER AJ, STIEF CG, JONAS U: Is there a significance of serotonin in the control of penile flaccidity and detumescence in the human male? Int. J. Impot. Res. (2002) 14(Suppl. 4):S40-S41.
63. LAL S, RIOS O, THAVUNDAYIL JX: Treatment of impotence with trazodone: a case report. J. Urol. (1990) 143:819-820.
64. ADAIKAN PG, NG SC, CHAN C, RATNAM SS: Oral trazodone in the treatment of total secondary impotence in a diabetic patient. Br. J. Urol. (1991) 63:771-772.
65. HORBY-PETERSEN J, NIELSEN FC, SCHMIDT PF: Penile tumescence after injection of a serotonin antagonist (ketanserin). Br. J. Urol. (1988) 62:277-278.
66. KURT Ü, ÖZKARDES H, ALTUG U, GERMIYANOGLU C, GÜRDAL M, EROL D: The efficacy of anti-serotonergic agents in the treatment of erectile dysfunction. J. Urol. (1994) 152:407-409.
67. DENNINGER JW, MARLETTA MA: Guanylate cyclase and the NO/cGMP signalling pathway. Biochim. Biophys. Acta (1999) 1411:334-350.
68. LEE YC, MARTIN E, MURAD F: Human recombinant soluble guanylyl cyclase: expression, purification, and regulation. Proc. Natl. Acad. Sci. USA (2000) 97:10763-10768.
69. HOBBS AJ: Soluble guanylate cyclase: an old therapeutic target re-visited. Br. J. Pharmacol. (2002) 136:637-640.
70. FRIEBE A, MÜLLERSHAUSEN F, SMOLENSKI A, WALTER U, SCHULTZ G, KOESLING D: YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. Mol. Pharmacol. (1998) 54:962-967.
71. MIZUSAWA H, HEDLUND P, BRIONI JD, SULLIVAN JP, ANDERSSON K-E: Nitric oxide independent activation of guanylate cyclase by YC-1 causes erectile responses in the rat. J. Urol. (2002) 167:2276-2281.
72. NAKANE M, HSIEH G, MILLER LN et al.: Activation of soluble guanylate cyclase causes relaxation of corpus cavernosum tissue: synergism of nitric oxide and YC-1. Int. J. Impot. Res. (2002) 14:121-127.
73. BISCHOFF E, SCHRAMM M, STRAUB A, FEURER A, STASCH JP: BAY 41-2272: a stimulator of soluble guanylyl cyclase induces nitric oxide dependent penile erection. Urology (2003) 61:464-467.
74. STRAUB A, STASCH JP, ALONSO-ALIJA C et al.: NO-independent stimulators of soluble guanylate cyclase. Bioorg. Med. Chem. Lett. (2001) 11:781-784.
75. STASCH JP, DEMBOWSKY K, PERZBORN E, STAHL E, SCHRAMM M: Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies. Br. J. Pharmacol. (2002) 135:344-355.
76. STASCH JP, ALONSO-ALIJA C, APELER H et al.: pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies. Br. J. Pharmacol. (2002) 135:333-343.
77. MORELAND RB, HSIEH GC, NAKANE M et al.: Novel soluble guanylate cyclase activators A-344905 and A-305619 activate sGC in vitro and facilitate penile erection in rats. J. Urol. (2002) 167(4, Suppl.):S938.
78. MILLER LN, NAKANE M, HSIEH GC et al.: A-350619: a novel activator of soluble guanylyl cyclase. Life Sci. (2003) 72:1015-1025.
79. SEIDLER M, ÜCKERT S, WALDKIRCH E et al.: In vitro effects of a novel class of nitric oxide (NO)-donating compounds on isolated human erectile tissue. Eur. Urol. (2002) 42:523-528.
80. RIFFAUD JP, BERNARBE J, GIULIANO F, JONES R, JEREMY J: Pharmacological profile of sildenafil nitrate (NCX 911) in various models of penile erection. Inflammation Res. (2001) 50(Suppl. 3):S84.
81. KUENSCH E, REINERS K, MÜLLER-MATTHEIS V, STROHMEYER T, ACKERMANN R, FREUND H-J: Neurological risk profile in organic erectile dysfunction. J. Neurol. Neurosurg. Psych. (1992) 55:275-281.
82. BECKER AJ, ÜCKERT S, STIEF CG et al.: Cavernous and systemic plasma levels of norepinephrine and epinephrine during different penile conditions in healthy males and patients with erectile dysfunction. Urology (2002) 59:281-286.
83. KRANE RJ, GOLDSTEIN I, SAENZ DE TEJADA I: Medical progress: Impotence. N. Engl. J. Med. (1989) 321:1648-1659.
84. WAGNER G, LACY S, LEWIS R, ZORGNIOTTI A: Buccal phentolamine - a pilot trial for male erectile dysfunction at three separate clinics. Int. J. Impot. Res. (1994) 6(Suppl. 1):D78.
85. TRAISH A, GUPTA S, GALLANT C, HUANG YH, GOLDSTEIN I: Phentolamine mesylate relaxes penile corpus cavernosum tissue by adrenergic and non-adrenergic mechanisms. Int. J. Impot. Res. (1998) 10:215-223.
86. GOLDSTEIN I,VASOMAX STUDY GROUP: Efficacy and safety of oral phentolamine (VASOMAX) for the treatment of minimal erectile dysfunction. J. Urol. (1998) 159(Suppl.):240.
87. GOLDSTEIN I: First-line therapy: Alpha-adrenergic receptor antagonists - clinical. Masters Course in Erectile Dysfunction, Boston MA, USA (1999) (Podium presentation).
88. BORG KE, ESBENSHADE KL, JOHNSON BH: Cortisol, Growth hormone, and testosterone concentrations during mating behaviour in bulls and boars. J. Anim. Sci. (1991) 69:230-240.
89. PENSON DF, NG C, RAJFER J, GONZALES-CAVIDAD NF: Adrenal control of erectile function and nitric oxide synthase in the rat penis. Endocrinology (1997) 138:3925-3932.
90. ARGIOLAS A, MELIS MR, GESSA GL: Yawning and penile erection: central dopamine - oxytocin - adrenocorticotropin connection. Ann. NY Acad. Sci. (1988) 525:330-337.
91. VERGONI AV, BERTOLINI P, MUTULIS F, WIKBERG JE, SCHIOTH HB: Differential influence of a selective melanocortin MC4 receptor antagonist (HS014) on melanocortin-induced behavioural effects in rats. Eur. J. Pharmacol. (1998) 362:95-101.
92. BRETTO LA, GORZALKA BB: Melatonin enhances sexual behaviour in the male rat. Physiol. Behav. (2000) 68:483-486.
93. MOUNTJOY KG, ROBBINS LS, MORTRUD MT, CONE RD: The cloning of a familiy of genes that encode the melanocortin receptors. Science (1992) 257:1248-1251.
94. VAN DER KRAAN M, ADAN RA, ENTWISTLE ML, GISPEN WH, BURBACH JP, TATRO JB: Expression of melanocortin-5 receptor in secretory epithelia supports a functional role in exocrine and endocrine glands. Endocrinology (1998) 139:2348-2355.
95. ISIDORI A, DI LUIGI L, CONTE D: ACTH 1 -17 and sexual behaviour. Ric. Clin. Lab. (1984) 14:247-251.
96. WESSELLS H, FUCIURELLI K, HANSEN J et al.: Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: a double-blind, placebo-controlled crossover study. J. Urol. (1998) 160:389-393.
97. WESSELLS H, LEVINE N, HADLEY ME, DORR R, HRUBY VJ: Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int. J. Impot. Res. (2000) 12(Suppl. 4):S74-S79.
98. LEVINE N, SHEFTEL SN, EYTAN T et al.: Induction of skin tanning by subcutaneous adminstration of a potent synthetic melanotropin. JAMA (1991) 266:2730-2736.
99. HULL KL, HARVEY S: Growth hormone: a reproductive endocrine-paracrine regulator. Rev. Reprod. (2000) 5:175-182.
100. CHANDRASHEKAR V, BARTKE A: The role of growth hormone in the control of gonadotropin secretion in adult male rats. Endocrinology (1998) 139:1067-1074.
101. JUUL A, ANDERSSON AM, PEDERSEN SA et al.: Effects of growth hormone replacement therapy on IGF-related parameters and on pituitary-gonadal axis in GH-deficient males. A double-blind, placebo-controlled crossover study. Horm. Res. (1998) 49:269-278.
102. JUNG GW, SPENCER EM, LUE TF: Growth hormone enhances regeneration of nitric oxide synthase-containing penile nerves after cavernous nerve neurotomy in rats. J. Urol. (1998) 160:1899-1904.
103. BÖGER RH, SKAMIRA C, BODE-BÖGER SM, BRABANT EG, VON ZUR MÜHLEN A, FRÖLICH JC: Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. J. Clin. Invest. (1996) 98:2706-2713.
104. BECKER AJ, ÜCKERT S, STIEF CG et al.: Possible role of human growth hormone in penile erection. J. Urol. (2000) 164:2138-2142.
105. BECKER AJ, ÜCKERT S, STIEF CG et al.: Serum levels of human growth hormone during different penile conditions in the cavernous and systemic blood of healthy men and patients with erectile dysfunction. Urology (2002) 59:609-614.
106. BECKER AJ, ÜCKERT S, STIEF CG, JONAS U: Growth hormone, somatomedins and men's health. Aging Male (2002) 5:258-262.
107. RUDMAN D, FELLER AG, NAGRAJ HS et al.: Effects of growth hormone in men over 60 years old. N. Engl. J. Med. (1990) 323:1-6.
108. PAPADAKIS MA, GRADY D, BLACK D et al.: Growth hormone replacement in older men improves body composition but not functional ability. Ann. Intern. Med. (1996) 124:708-716.
109. JEFFCOATE W: Can growth hormone therapy cause diabetes? Lancet (2000) 355:589-590.
110. MONSON JP, BENGTSSON BA, ABS R, FELDT-RASMUSSEN U, WÜSTER C: Can growth hormone therapy cause diabetes? Letter to the Editor. Lancet (2000) 355:1728.
111. CHAN JM, STAMPFER MJ, GIOVANNUCCI E et al.: Plasma insulin-like growth factor 1 and prostate cancer risk a prospective study. Science (1998) 279:563-566.
112. ZORGNIOTTI AW, LIZZA EF: Effect of large doses of the nitric oxide precursor L-arginine on erectile dysfunction. Int. J. Impot. Res. (1994) 6:33-35.
113. HO GD, SILVERMAN L, BERCOVICI A et al.: Synthesis and evaluation of potent and selective cGMP-phosphodiesterase inhibitors. Bioorg. Med. Chem. Lett (1999) 9:7-12.
114. ROTELLA DP, SUN Z, ZHU J et al.: Optimization of substituted N-3-benzylimidazoquinazolinone sulfonamides as potent and selective PDE5 inhibitors. J. Med. Chem. (2000) 43:5037-5043.
115. GUAY D, HAMEL P, BLOUIN M et al.: Discovery of L-791.943: a potent, selective, non-emetic and orally active phosphodiesterase 4 inhibitor. Bioorg. Med. Chem. Lett. (2002) 12:1457-1461.